TEASE Program Builds Case for Gildeuretinol in Stargardt - Takeaways - MDSpire

TEASE Program Builds Case for Gildeuretinol in Stargardt

Philip J. Ferrone, MD, FASRS, reviewed data on gildeuretinol and discussed the ongoing NORTHSTAR pivotal trial at Retina World Congress.

  • By

  • Philip Ferrone, MD

  • May 14, 2026

  • 3 min

Share

  • 1

    The TEASE program evaluates gildeuretinol's efficacy in reducing atrophic lesion growth in Stargardt disease.

  • 2

    Gildeuretinol reduces toxic vitamin A dimerization by up to 80% and is metabolized like vitamin A.

  • 3

    TEASE-1 and TEASE-2 trials demonstrated significant reductions in lesion growth and EZ loss in Stargardt patients.

  • 4

    The ongoing NORTHSTAR phase 3 trial aims to assess gildeuretinol's safety and efficacy in advanced Stargardt disease.

  • 5

    Gildeuretinol has shown mild to moderate tolerability with no significant safety signals reported in the studies.

Original Source(s)

TEASE Program Builds Case for Gildeuretinol in Stargardt

  • by Philip Ferrone, MD

  • May 14, 2026

Related Content

Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses

AI in Clinical Decision Support Systems: Promising Applications and Strategies for Managing Data Challenges

FDA Updates: Retina Trials and Regulatory Pathways

William M. Boyd, MD, director of the FDA’s Division of Ophthalmology, discussed the agency’s evolving approaches to clinical evidence, trial design, and expedited regulatory pathways at the 2026 Retina World Congress meeting.